NCT00189280 2022-02-22
Aldara for the Treatment of Large and/or Multiple sBCC
Viatris Inc.
Phase 3 Completed
Clinical Trials
9 trialsNCT00189241 2022-02-07
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Viatris Inc.
Phase 3 Completed
NCT00294320 2022-02-07
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Viatris Inc.
Phase 3 Completed
NCT01686152 2020-11-24
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
Phase 3 Completed
NCT00948428 2020-09-04
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldaraâ„¢ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02120898 2019-12-13
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actavis Inc.
Phase 3 Completed
NCT00674739 2011-05-24
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00129519 2010-07-16
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00859105 2009-03-10
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Apotex Inc.
Phase 3 Completed